CAC
DGX icon

Cowen and Company’s Quest Diagnostics DGX Stock Holding History

Cowen and Company’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,659
Closed -$204K – 692
2022
Q3 		$204K Buy
+1,659
New +$218K 0.02% 178
2022
Q2 		– Sell
-1,703
Closed -$233K – 676
2022
Q1 		$233K Buy
+1,703
New +$237K 0.02% 224

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cowen and Company's DGX Position: Q4 2022 in Review

Cowen and Company sold out of Quest Diagnostics (DGX) in Q4 2022, closing a stake of 1,659 shares — an estimated $204K sold.

Cowen and Company first reported a position in DGX in Q1 2022 and held it in 2 quarters. The position peaked at $233K in Q1 2022. 879 funds tracked by Wall St. Rank hold DGX as of Q4 2022.

  • Cowen and Company reported no remaining Quest Diagnostics position as of Q4 2022 after selling out during the quarter.
  • Cowen and Company sold 1,659 Quest Diagnostics shares in Q4 2022, an estimated $204K.
  • Cowen and Company first reported a position in Quest Diagnostics in Q1 2022 and held it in 2 quarters.
  • Cowen and Company's Quest Diagnostics position peaked at $233K in Q1 2022.
  • 879 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2022.

Based on Cowen and Company's 13F filing for Q4 2022, filed 9 Feb 2023.